Affimed NV at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, everyone. My name is Amy Shin, and I'm part of the health care team at JPMorgan. It is with great pleasure that I introduce Dr. Adi Hoess, CEO of Affimed. And with that, I'll hand it off to Dr. Hoess. Thank you.
Thank you, Amy, for the introduction and good day, all, for listening today to my presentation about Affimed.
And as you may well know, we are actualizing an untapped potential in the immune system called the innate immune system. We believe that this can indeed drive a revolution in cancer treatment as the innate immune system has a very good potential, in particular with the activation of natural killer cells and macrophages. You may not only be able to drive these cells to attack the tumor, but also kick off the entire immune system, comprising also the adaptive components such as T cells. Overall, it should improve patients' lives and ideally also lead to some cures.
We do this by developing bispecific innate cell engagers. Why do we call them
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
